Key statistics
On Monday, Sichuan Kelun-Biotech Biopharmaceutical Co Ltd (6990:HKG) closed at 412.60, -28.98% below its 52-week high of 581.00, set on Oct 03, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 422.00 |
|---|---|
| High | 422.00 |
| Low | 407.00 |
| Bid | 412.00 |
| Offer | 412.60 |
| Previous close | 418.60 |
| Average volume | 393.82k |
|---|---|
| Shares outstanding | 233.19m |
| Free float | 112.76m |
| P/E (TTM) | -- |
| Market cap | 96.21bn HKD |
| EPS (TTM) | -3.65 HKD |
Data delayed at least 15 minutes, as of Feb 16 2026 04:08 GMT.
More ▼
- Kelun-Biotech Announces Fourth Indication for Sacituzumab Tirumotecan (sac-TMT) Approved by NMPA in HR+/HER2- Breast Cancer
- Kelun-Biotech Showcases Innovative Achievements and Future Development Strategy at the 44th Annual JPM Healthcare Conference
- Kelun-Biotech to Attend the 44th J.P. Morgan Healthcare Conference, Sharing Its Business Progresses and Innovation Strategies
- Kelun-Biotech Receives Investigational New Drug Approval for ITGB6-Targeted ADC SKB105 from the NMPA
- Kelun-Biotech Announces Breakthrough Therapy Designation Granted in China for Sacituzumab Tirumotecan (sac-TMT) in Combination with Immunotherapy Pembrolizumab for First-Line Treatment of PD-L1-Positive NSCLC
- /C O R R E C T I O N -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd./
- Kelun-Biotech Announces Phase III Trial of Sac-TMT in Combination with KEYTRUDA® (pembrolizumab) as First-Line Treatment for PD-L1-Positive NSCLC Met Primary Endpoint
More ▼
